The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases

Liu, Ronghua; Ma, Xiangyi; Wang, Hongyan; Xi, Yandong; Qian, Min; Yang, Wei; Luo, Danfeng; Fan, Liangsheng; Xia, Xi; Zhou, Jianfeng; Li, Meng; Wang, Shixuan; Ma, Ding

doi:10.1007/s00109-013-1093-2

Cited by 18 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, researchers fused molecular drugs to TMTP1 for targeting therapy. The fused drugs show more safety and efficiency in tumor therapy in a mouse model [13][14][15]17]. Thus, TMTP1 may be a powerful candidate therapeutic agent for metastatic tumors based on its specific targeting.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, in this study, we labeled TMTP1 with 99mTechnetium and evaluated its potential to target highly metastatic ovarian tumors in vitro and in vivo. Meanwhile, we chose highly metastatic MNK-45 cell as a positive control in terms of previous research [12][13][14]17]. …”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

“…In this study, we chose highly metastatic cell MNK-45 as a positive control which TMTP1 can specifically bind to [12][13][14]16,17]. The cell uptake of 99m Tc-HYNIC-TMTP1 was evaluated in the different metastatic cancer cell lines MNK-45, SKOV3 and SKOV3.ip.…”

Section: Cell Uptake Assaymentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT

Cheng

Dong

et al. 2015

Nuclear Medicine and Biology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT

Cheng

Dong

et al. 2015

Nuclear Medicine and Biology

Self Cite

View full text Add to dashboard Cite

“…sTRAIL, a soluble form of TRAIL, can be proteolytically cleaved, and can maintain its original tumor cell killing activity 6, 7 . sTRAIL consists of 168 carboxy-terminal amino acids from the TRAIL extracellular domain (19.6 kD) 8 . Most human primary cells exhibited no obvious cytotoxicity as a result of soluble TRAIL variants, which were also tolerated by chimpanzees and mice 9 .…”

Section: Introductionmentioning

confidence: 99%

“…A few recombinant sTRAIL derivatives exhibit antitumor activities in vitro and in mouse models bearing tumors. sTRAIL is a new and original therapeutic approach, which can induce apoptosis in diverse tumors 8 . However, TRAIL is limited for therapeutic purposes due to cytotoxicity in hepatocytes 10, 11 .…”

Section: Introductionmentioning

confidence: 99%

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

Huang

Sha

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells and augments chemotherapeutics in vivo. Here, we developed sTRAIL-iRGD, a recombinant protein consisting of sTRAIL fused to CRGDKGPDC, a C-terminal end binding peptide with an integrin-binding arginine-glycine-aspartic acid (iRGD) motif. CRGDKGPDC is a tumor-homing peptide with high penetration into tumor tissue and cells. We found that sTRAIL-iRGD internalized into cultured gastric cancer tumor cells and localized to both the tumor mass in vivo and three-dimensional multicellular spheroids in vitro. sTRAIL-iRGD had an antitumor effect in tumor cell lines, multicellular spheroids and nude mice with tumors. Repeated treatment with sTRAIL-iRGD reduced tumor growth and volume in vivo. Mice treated with sTRAIL-iRGD and paclitaxel (PTX) in combination showed no sign of sTRAIL-iRGD-related liver toxicity. Our data suggest that sTRAIL-iRGD is a promising anti-gastric cancer agent with high selectivity and limited systemic toxicity.

show abstract

Syntheses and preliminary evaluation of [¹⁸F]AlF‐NOTA‐G‐TMTP1 for PET imaging of high aggressive hepatocellular carcinoma

Zhang

Shi

et al. 2016

Contrast Media & Molecular

View full text Add to dashboard Cite

The goal of this study is to evaluate a new (18) F-labeled imaging agent for diagnosing high metastatic (aggressive) hepatocellular carcinoma using positron emission tomography (PET). The new (18) F-labeled imaging agent [(18) F]AlF-NOTA-G-TMTP1 was synthesized and radiolabeled with (18) F using NOTA-AlF chelation method. The tumor-targeting characteristics of [(18) F]AlF-NOTA-G-TMTP1 was assessed in HepG2, SMCC-7721, HCC97L and HCCLM3 xenografts. The total synthesis time was about 20 min with radiochemical yield of 25 ± 6%. The specific activity was about 11.1-14.8 GBq/µmol at the end of synthesis based on the amount of peptide used and the amount of radioactivity trapped on the C18 column. The log P value of [(18) F]AlF-NOTA-G-TMTP1 was -3.166 ± 0.022. [(18) F]AlF-NOTA-G-TMTP1 accumulated in SMCC-7721 and HCCLM3 tumors (high metastatic potential) in vivo and result in tumor/muscle (T/M) ratios of 4.5 ± 0.3 and 4.7 ± 0.2 (n = 4) as measured by PET at 40 min post-injection (p.i.). Meanwhile, the tumor/muscle (T/M) ratios of HepG2 and HCC97L tumors (low metastatic potential) were1.6 ± 0.3 and 1.8 ± 0.4. The tumor uptake of [(18) F]AlF-NOTA-G-TMTP1 could be inhibited 61.9% and 57.6% by unlabeled G-TMTP1 in SMCC-7721 and HCCLM3 xenografts at 40 min p.i., respectively. Furthermore, [(18) F]AlF-NOTA-G-TMTP1 showed pretty low activity in the liver and intestines in all tumor bearing mice, such in vivo distribution pattern would be advantageous for the detection of hepatic carcinoma. Overall, [(18) F]AlF-NOTA-G-TMTP1 may specifically target high metastatic or/and aggressive hepatocellular carcinoma with low background activity and, therefore, holds the potential to be used as an imaging agent for detecting tumor lesions within the liver area. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases

Cited by 18 publications

References 32 publications

Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT

Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

Syntheses and preliminary evaluation of [¹⁸F]AlF‐NOTA‐G‐TMTP1 for PET imaging of high aggressive hepatocellular carcinoma

Contact Info

Product

Resources

About

The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases

Cited by 18 publications

References 32 publications

Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT

Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

Syntheses and preliminary evaluation of [18F]AlF‐NOTA‐G‐TMTP1 for PET imaging of high aggressive hepatocellular carcinoma

Contact Info

Product

Resources

About

Syntheses and preliminary evaluation of [¹⁸F]AlF‐NOTA‐G‐TMTP1 for PET imaging of high aggressive hepatocellular carcinoma